LU92550I2 - Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables - Google Patents

Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables Download PDF

Info

Publication number: LU92550I2
Authority: LU; Luxembourg
Prior art keywords: lurasidone; optionally; pharmaceutically acceptable; acceptable salts; free base
Prior art date: 2005-05-26

Application number

LU92550C

Other languages

English (en)

Original Assignee

Sumitomo Dainippon Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-26

Filing date

2014-09-18

Publication date

2015-11-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92550(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-09-18 Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd

2015-11-02 Publication of LU92550I2 publication Critical patent/LU92550I2/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Inorganic Chemistry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Psychiatry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

LU92550C 2005-05-26 2014-09-18 Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables LU92550I2 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2005153508		2005-05-26

Publications (1)

Publication Number	Publication Date
LU92550I2 true LU92550I2 (fr)	2015-11-02

Family

ID=37452103

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU92550C LU92550I2 (fr)	2005-05-26	2014-09-18	Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables

Country Status (22)

Country	Link
US (5)	US8729085B2 (fr)
EP (2)	EP1884242B1 (fr)
JP (2)	JP4733120B2 (fr)
KR (2)	KR101552033B1 (fr)
CN (2)	CN101184489B (fr)
AU (1)	AU2006250340C1 (fr)
BR (2)	BR122020005056B1 (fr)
CA (1)	CA2606510C (fr)
CY (2)	CY1114118T1 (fr)
DK (2)	DK1884242T3 (fr)
ES (2)	ES2535478T3 (fr)
FR (1)	FR14C0069I2 (fr)
HK (1)	HK1108379A1 (fr)
HU (1)	HUS1400051I1 (fr)
LU (1)	LU92550I2 (fr)
MX (1)	MX2007014872A (fr)
NL (1)	NL300690I2 (fr)
PL (1)	PL1884242T3 (fr)
PT (1)	PT1884242E (fr)
RU (1)	RU2398586C3 (fr)
SI (1)	SI1884242T1 (fr)
WO (1)	WO2006126681A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1886678B1 (fr) *	2005-05-18	2017-04-19	Sumitomo Dainippon Pharma Co., Ltd.	Comprimé stable contenant de la droxidopa
CN101184489B (zh) *	2005-05-26	2011-01-19	大日本住友制药株式会社	药物组合物
KR20100121483A (ko) *	2008-02-11	2010-11-17	다이닛본 스미토모 세이야꾸 가부시끼가이샤	용출성이 개선된 정제
ES2400774T3 (es)	2008-06-13	2013-04-12	Dainippon Sumitomo Pharma Co., Ltd.	Tableta que se disgrega rápidamente en la cavidad oral y método para producción de la misma
JP5694773B2 (ja) *	2008-09-30	2015-04-01	テバ製薬株式会社	圧縮成型製剤およびその製造方法
MX342330B (es)	2009-05-19	2016-09-26	Celgene Corp	Formulaciones de 4-amino-2-(2, 6-dioxopiperidin-3-il) isoindolin-1, 3-diona.
JP5893616B2 (ja) *	2010-10-18	2016-03-23	大日本住友製薬株式会社	注射用徐放性製剤
WO2012063246A1 (fr) *	2010-11-11	2012-05-18	Mapi Pharma Ltd.	Forme amorphe du chlorhydrate de lurasidone
WO2012107890A2 (fr) *	2011-02-10	2012-08-16	Ranbaxy Laboratories Limited	Formes cristallines de chlorhydrate de lurasidone
US9433620B2 (en) *	2011-05-13	2016-09-06	Cadila Healthcare Limited	Pharmaceutical compositions of lurasidone
US8981095B2 (en)	2011-07-28	2015-03-17	Mapi Pharma Ltd.	Intermediate compounds and process for the preparation of lurasidone and salts thereof
CN102911169B (zh) *	2011-08-02	2015-05-06	上海医药工业研究院	一种卢拉西酮的制备方法
WO2013061338A1 (fr)	2011-08-24	2013-05-02	Cadila Healthcare Limited	Compositions pharmaceutiques de silodosine
CN103446071B (zh) *	2012-05-29	2017-12-19	江苏豪森药业集团有限公司	一种口服片剂及其制备方法和用途
CN102688209A (zh) *	2012-06-21	2012-09-26	李兴惠	鲁拉西酮片和制备方法
CN102688210A (zh) *	2012-06-21	2012-09-26	李兴惠	鲁拉西酮的药物组合物和制备方法
CN106074414B (zh) *	2012-07-12	2019-01-18	成都康弘药业集团股份有限公司	一种含有鲁拉西酮的口腔崩解片及其制备方法
CN103006661B (zh) *	2012-12-06	2015-02-18	江苏先声药物研究有限公司	一种含有盐酸鲁拉西酮的制剂及其制备方法
US20150157628A1 (en) *	2013-12-11	2015-06-11	Saravanan Kannusamy	Pharmaceutical compositions of Lurasidone and Process for preparation thereof
WO2016012898A1 (fr)	2014-07-25	2016-01-28	Lupin Limited	Composition pharmaceutique orale de lurasidone
CN104606133A (zh) *	2015-01-07	2015-05-13	万特制药(海南)有限公司	鲁拉西酮口服混悬液及其制备方法
WO2016139683A2 (fr) *	2015-03-05	2016-09-09	Jubilant Generics Limited	Compositions pharmaceutiques de lurasidone et son procédé de préparation
DE102016205950A1 (de) *	2016-04-08	2017-10-12	Dietrich Seidel	Mittel zur Verwendung bei entzündlichen Zuständen der Schleimhäute
WO2018083117A1 (fr) *	2016-11-02	2018-05-11	Sanovel Ilac Sanayi Ve Ticaret A.S.	Compositions pharmaceutiques orales solides de chlorhydrate de lurasidone
CN108567758A (zh) *	2017-03-08	2018-09-25	湖南洞庭药业股份有限公司	盐酸鲁拉西酮片剂及其制备方法
CN107854445A (zh) *	2017-12-17	2018-03-30	佛山市弘泰药物研发有限公司	一种盐酸鲁拉西酮分散片及其制备方法
CN107875122A (zh) *	2017-12-17	2018-04-06	佛山市弘泰药物研发有限公司	一种盐酸鲁拉西酮自微乳制剂及其制备方法
CN107854446A (zh) *	2017-12-19	2018-03-30	佛山市弘泰药物研发有限公司	一种盐酸鲁拉西酮口崩片及其制备方法
WO2019167978A1 (fr)	2018-02-28	2019-09-06	大日本住友製薬株式会社	Préparation pharmaceutique de type suspension aqueuse à dissolution contrôlée
EP3772993A1 (fr)	2018-04-10	2021-02-17	Z-Catering Mitte GmbH	Dispositif de réchauffage d'un plat conservé dans des unités d'emballage, destiné à préparer une restauration collective
KR102286499B1 (ko) *	2018-04-13	2021-08-05	주식회사 삼양홀딩스	레날리도마이드를 포함하는 약제학적 조성물
WO2022042646A1 (fr) *	2020-08-26	2022-03-03	浙江华海药业股份有限公司	Composition de chlorhydrate de lurasidone et son procédé de préparation
AT17300U3 (de) *	2020-12-03	2022-02-15	G L Pharma Gmbh	Feste orale pharmazeutische Zusammensetzung
US20240100022A1 (en)	2020-12-23	2024-03-28	Sumitomo Pharma Co., Ltd.	Oral solid preparation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4600579A (en) *	1983-06-07	1986-07-15	Mallinckrodt, Inc.	N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
US4551177A (en)	1984-04-23	1985-11-05	National Starch And Chemical Corporation	Compressible starches as binders for tablets or capsules
US4609675A (en)	1984-08-17	1986-09-02	The Upjohn Company	Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4837031A (en)	1987-09-17	1989-06-06	Mallinckrodt, Inc.	Compositions containing ibuprofen
US5047246A (en)	1988-09-09	1991-09-10	Bristol-Myers Company	Direct compression cyclophosphamide tablet
US5104648A (en)	1989-02-02	1992-04-14	Mallinckrodt Specialty Chemicals Company	High ibuprofen content granulations
US4911921A (en)	1989-02-02	1990-03-27	Mallinckrodt, Inc.	High ibuprofen content granulations
JP2800953B2 (ja)	1990-07-06	1998-09-21	住友製薬株式会社	新規なイミド誘導体
US5605889A (en)	1994-04-29	1997-02-25	Pfizer Inc.	Method of administering azithromycin
ES2181868T3 (es)	1995-02-28	2003-03-01	Aventis Pharma Inc	Composicion farmaceutica para compuestos de piperidinoalcanol.
JP4022269B2 (ja) *	1995-05-26	2007-12-12	協和醗酵工業株式会社	医薬組成物
TR200001056T2 (tr)	1997-10-20	2000-09-21	Dainippon Pharmaceutical Co., Ltd.	Hızlı çözülen farmasötik terkipler.
JP4063386B2 (ja) *	1998-01-29	2008-03-19	キッセイ薬品工業株式会社	速放性経口医薬品組成物
US6150366A (en)	1998-06-15	2000-11-21	Pfizer Inc.	Ziprasidone formulations
EA005291B1 (ru) *	1999-03-31	2004-12-30	Янссен Фармацевтика Н.В.	Применение предварительно желатинированного крахмала в композиции с контролируемым высвобождением
US6586617B1 (en)	1999-04-28	2003-07-01	Sumitomo Chemical Takeda Agro Company, Limited	Sulfonamide derivatives
WO2001076557A1 (fr) *	2000-04-10	2001-10-18	Sumitomo Pharmaceuticals Co., Ltd.	Preparations a liberation prolongee
JP4868695B2 (ja) *	2000-09-22	2012-02-01	大日本住友製薬株式会社	崩壊性が良好な経口製剤
ATE468325T1 (de)	2001-03-19	2010-06-15	Dainippon Sumitomo Pharma Co	Arylsubstituierte alicyclische verbindung und diese enthaltende medizinische zusammensetzung
GB0209265D0 (en)	2002-04-23	2002-06-05	Novartis Ag	Organic compounds
EP1944030B1 (fr) *	2002-08-22	2018-08-01	Sumitomo Dainippon Pharma Co., Ltd.	Agent de traitement de schizophrénie
MXPA05001707A (es)	2002-08-30	2005-04-19	Pharmacia Corp	Formas de dosificacion farmaceutica solidas que presentan un perfil de liberacion de farmaco reproducible,.
JPWO2004078173A1 (ja) *	2003-02-05	2006-06-08	塩野義製薬株式会社	溶出性の改善された錠剤
EP2316442A1 (fr)	2003-09-12	2011-05-04	Amgen Inc.	Composition à base de composé actif aux récepteurs au calcium, à vitesse de dissolution rapide
CN1913876B (zh)	2003-12-09	2013-06-26	大日本住友制药株式会社	含药物的颗粒和包含这种颗粒的固体制剂
WO2006096439A2 (fr)	2005-03-04	2006-09-14	Boehringer Ingelheim International Gmbh	Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
CN101184489B (zh)	2005-05-26	2011-01-19	大日本住友制药株式会社	药物组合物

2006
- 2006-05-26 CN CN2006800182234A patent/CN101184489B/zh not_active Expired - Fee Related
- 2006-05-26 PL PL06746900T patent/PL1884242T3/pl unknown
- 2006-05-26 CA CA2606510A patent/CA2606510C/fr active Active
- 2006-05-26 SI SI200631567T patent/SI1884242T1/sl unknown
- 2006-05-26 WO PCT/JP2006/310571 patent/WO2006126681A1/fr active Application Filing
- 2006-05-26 DK DK06746900.7T patent/DK1884242T3/da active
- 2006-05-26 JP JP2007517921A patent/JP4733120B2/ja active Active
- 2006-05-26 RU RU2007148997A patent/RU2398586C3/ru not_active Application Discontinuation
- 2006-05-26 BR BR122020005056-0A patent/BR122020005056B1/pt active IP Right Grant
- 2006-05-26 CN CN2010105647842A patent/CN102048734B/zh not_active Expired - Fee Related
- 2006-05-26 EP EP06746900.7A patent/EP1884242B1/fr active Active
- 2006-05-26 PT PT67469007T patent/PT1884242E/pt unknown
- 2006-05-26 ES ES11181100.6T patent/ES2535478T3/es active Active
- 2006-05-26 BR BRPI0611409A patent/BRPI0611409B8/pt active IP Right Grant
- 2006-05-26 KR KR1020137027051A patent/KR101552033B1/ko active IP Right Grant
- 2006-05-26 MX MX2007014872A patent/MX2007014872A/es active IP Right Grant
- 2006-05-26 DK DK11181100.6T patent/DK2422783T3/en active
- 2006-05-26 AU AU2006250340A patent/AU2006250340C1/en active Active
- 2006-05-26 KR KR1020077027270A patent/KR101380088B1/ko active IP Right Grant
- 2006-05-26 US US11/919,678 patent/US8729085B2/en active Active
- 2006-05-26 ES ES06746900T patent/ES2408687T3/es active Active
- 2006-05-26 EP EP20110181100 patent/EP2422783B1/fr active Active
2008
- 2008-03-03 HK HK08102367.3A patent/HK1108379A1/xx unknown
2011
- 2011-03-18 JP JP2011061211A patent/JP5285105B2/ja active Active
2013
- 2013-05-14 CY CY20131100384T patent/CY1114118T1/el unknown
2014
- 2014-02-18 US US14/183,283 patent/US8883794B2/en active Active
- 2014-09-15 HU HUS1400051C patent/HUS1400051I1/hu unknown
- 2014-09-16 NL NL300690C patent/NL300690I2/nl unknown
- 2014-09-16 FR FR14C0069C patent/FR14C0069I2/fr active Active
- 2014-09-18 CY CY2014039C patent/CY2014039I2/el unknown
- 2014-09-18 LU LU92550C patent/LU92550I2/fr unknown
- 2014-10-10 US US14/512,189 patent/US9555027B2/en active Active
2015
- 2015-06-08 US US14/733,204 patent/US9907794B2/en active Active
2018
- 2018-02-06 US US15/889,893 patent/US20180161322A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2422783B1 (fr)	2015-04-08
JP4733120B2 (ja)	2011-07-27
DK1884242T3 (da)	2013-05-06
RU2007148997A (ru)	2009-07-10
CY1114118T1 (el)	2016-06-22
BR122020005056B1 (pt)	2023-01-10
ES2408687T3 (es)	2013-06-21
BRPI0611409B8 (pt)	2021-05-25
US8883794B2 (en)	2014-11-11
US20140235651A1 (en)	2014-08-21
ES2535478T3 (es)	2015-05-12
BR122020005056A2 (fr)	2010-11-23
US9907794B2 (en)	2018-03-06
FR14C0069I2 (fr)	2015-11-20
CN101184489A (zh)	2008-05-21
HUS1400051I1 (hu)	2016-10-28
KR20080012306A (ko)	2008-02-11
HK1108379A1 (en)	2008-05-09
JP2011126915A (ja)	2011-06-30
US9555027B2 (en)	2017-01-31
PT1884242E (pt)	2013-05-21
CA2606510C (fr)	2014-07-22
US20090143404A1 (en)	2009-06-04
BRPI0611409B1 (pt)	2020-12-29
DK2422783T3 (en)	2015-05-11
AU2006250340A1 (en)	2006-11-30
MX2007014872A (es)	2008-02-15
US20180161322A1 (en)	2018-06-14
BR122020005056A8 (pt)	2022-11-22
BRPI0611409A8 (pt)	2015-12-15
CY2014039I1 (el)	2016-06-22
CY2014039I2 (el)	2016-06-22
NL300690I2 (nl)	2017-11-02
EP2422783A1 (fr)	2012-02-29
US8729085B2 (en)	2014-05-20
KR101552033B1 (ko)	2015-09-09
CA2606510A1 (fr)	2006-11-30
RU2398586C2 (ru)	2010-09-10
SI1884242T1 (sl)	2013-07-31
KR20130122019A (ko)	2013-11-06
CN101184489B (zh)	2011-01-19
PL1884242T3 (pl)	2013-09-30
AU2006250340B2 (en)	2012-02-09
AU2006250340C1 (en)	2014-06-12
WO2006126681A1 (fr)	2006-11-30
FR14C0069I1 (fr)	2014-10-24
JP5285105B2 (ja)	2013-09-11
EP1884242B1 (fr)	2013-04-17
EP1884242A1 (fr)	2008-02-06
RU2398586C3 (ru)	2017-10-04
CN102048734B (zh)	2013-11-20
US20150265611A1 (en)	2015-09-24
KR101380088B1 (ko)	2014-04-10
CN102048734A (zh)	2011-05-11
BRPI0611409A2 (pt)	2010-11-23
US20150056284A1 (en)	2015-02-26
JPWO2006126681A1 (ja)	2008-12-25
EP1884242A4 (fr)	2009-07-01

Publication	Publication Date	Title
LU92550I2 (fr)	2015-11-02	Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables
LU92035I2 (fr)	2012-08-28	Vemurafenib et les sels pharmaceutiquement acceptables de celui-ci, sous toutes les formes bénéficiant de la protection conférée par le brevet de base
FR22C1008I1 (fr)	2022-04-29	Composition immunogène
LU92200I1 (fr)	2020-06-02	Linaclotide et toute forme thérapeutique équivalente de celui-ci, protégé par le brevet de base, y compris des sels pharmaceutiquement acceptables
LU92374I2 (fr)	2015-11-02	Alogliptin sous toutes ses formes telles que protégées par le brevet de base
LU92327I2 (fr)	2014-02-05	Ponatinib sous toutes ses formes telles que protégées par le brevet de base
LU92376I2 (fr)	2015-10-29	Alogliptin sous toutes ses formes telles que protégées par le brevet de base, combiné avec pioglitazone sous toutes ses formes telles que protégées par le brevet de base
LU92864I2 (fr)	2016-01-06	Cobicistat ou un de ses sels pharmaceutiquement acceptables
LU92595I2 (fr)	2015-11-02	Siméprévir, ou l'un de ses sels pharmaceutiquementacceptables, incluant siméprévir sodium
LU92137I2 (fr)	2014-01-18	Ruxolitinib, ou un de ses sels pharmaceutiquement acceptables
EP1856123A4 (fr)	2010-12-29	Inhibiteurs de mdm2, sous forme de petites molecules et utilisations de ces derniers
FR2881652B1 (fr)	2007-05-25	Forme pharmaceutique orale microparticulaire anti-mesuage
RS50611B (sr)	2010-06-30	"BEZILAT SO 7 - (2- (4- (3 – TRIFLUOROMETIL - FENIL) -1, 2, 3, 6" TETRAHIDRO - PIRID-1- ILI)ETIL)IZOHINOLlNA, NJENO DOBIJANJE I NJENA TERAPEUTSKA PRIMENA
PL378587A1 (pl)	2007-07-09	Sposób wytwarzania (S)-(-)-2-amino-6-n-propyloamino-4,5,6,7-tetrahydrobenzotiazolu i/lub jego soli
DE602006000763D1 (de)	2008-05-08	Kissenkörper
EP1846024A4 (fr)	2009-07-29	Mutants mycobacteriens afectant l'apoptose chez l'hôte
ITBO20040561A1 (it)	2004-12-10	Macchina per la lavorazione di lamiere
FR2881048B1 (fr)	2009-07-17	Composition parfumante sous forme compactee
ITMI20051435A1 (it)	2007-01-26	Macchina per la realizzazione di capi di abbigliamento e simili
ITTO20040826A1 (it)	2005-02-23	Macchina cordonatrice-piegatrice per la realizzazione di articoli cartotecnici e di legatoria
FR2884969B1 (fr)	2008-04-11	Integration d'elements capacitifs sous forme de ceramique perovskite
ITMI20040443A1 (it)	2004-06-08	Prpcesso per la preparazione di ..15-16-17-cheto-steroidi e loro uso nella sintesi di composti farmacologicamente attivi
ITMI20040505A1 (it)	2004-06-17	Macchina per la frantumazione di bottiglie
ITMI20062515A1 (it)	2008-06-28	Procedimento per la preparazione di 3,6-di-o-aceti-d-glicali
ITVR20030013A1 (it)	2004-08-06	Procedimento per l'ottenimento di lastre dotate di